Today, PARP-inhibitors are currently used for the treatment of prostate cancer patients with germinal or somatic mutations in BRCA1 and BRCA2 genes, which results in therapeutically resistant cancers [20,21]. This evidence concerns the gene BRCA2 and prostate cancer.